Dupixent Asthma denied as duplicate or overlapping therapy by Aetna?

Aetna's specific coverage criteria for dupixent asthma are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Aetna Denied Dupixent for Asthma as Duplicate Therapy — and How to Appeal

Aetna's "duplicate therapy" denial for dupilumab (Dupixent) in asthma typically arises when your claim is processed alongside — or shortly after — a claim for another biologic or targeted therapy for the same condition. The plan's system flags the combination as redundant. This does not mean you cannot use dupilumab; it means Aetna requires evidence that your physician has made a deliberate, clinically justified decision to use this specific agent rather than (or in transition from) the other therapy.

### Why This Denial Is Appealable

Duplicate-therapy edits are automated flags, not individualized clinical decisions. Dupilumab has a distinct mechanism of action from other biologics used in severe asthma, and your physician may have documented clinical reasons — such as an inadequate response to the prior agent, a specific inflammatory phenotype, or a transition plan — that justify the prescription. ERISA §503 and ACA §2719 require Aetna to conduct a genuine clinical review, not simply defer to an automated edit.

### Your Appeal Timeline

• Internal appeal: File within the deadline on your denial notice (commonly 180 days for ERISA plans). Decisions typically within 30–60 days; expedited within 72 hours for urgent cases.
• External review: After internal denial, you generally have approximately four months to request independent external review. Expedited review is available for urgent situations.

### Documentation to Gather

1. Diagnosis confirmation — pulmonary function tests, specialist notes, and chart documentation confirming severe or uncontrolled asthma and the relevant inflammatory phenotype. 2. Prior biologic history — if you were on another biologic, document dates of use, reason for transition or overlap, and your prescriber's explanation of why dupilumab is the appropriate agent going forward. 3. Clinical severity documentation — exacerbation frequency, oral corticosteroid burden, emergency or hospital visits, and quality-of-life measures from your chart. 4. Prescriber medical-necessity letter — your physician should explain why dupilumab is clinically distinct from any other concurrent therapy, why both (or the transition) is appropriate, and how your asthma phenotype aligns with the FDA-approved indication for dupilumab. 5. Transition or discontinuation plan — if applicable, a letter confirming the prior biologic is being or has been discontinued.

### Criteria-Mapping Structure

Obtain Aetna's published clinical policy for dupilumab in asthma. Map each requirement to your chart:

| Policy Requirement | Chart Evidence That Meets It | |---|---| | Confirmed severe/uncontrolled asthma | [Diagnosis note, PFT date] | | Appropriate phenotype per FDA labeling | [Eosinophil level or type-2 marker documented in chart] | | No clinically unjustified duplication | [Prescriber's explanation of transition or clinical rationale] |

Review the FDA-approved prescribing information for dupilumab and Aetna's current clinical policy to ensure your appeal letter addresses every stated criterion with a corresponding chart fact.